*Values are no. (%) except as indicated. Fisher exact test used for comparative statistics when >20% of expected cell counts were <5. Boldface indicates p<0.05. CRE, carbapenem-resistant Enterobacterales; ESBL-E, extended-spectrum β-lactamase–producing Enterobacterales. †ESBL-E surveillance was completed for 6 months during 2019. ‡Clinical characteristics were available for cases with completed case report forms only. §Cases could have >1 underlying condition associated with culture. Underlying conditions are further defined as follows: premature birth, birth before the week 37 of pregnancy, selected if medical record indicated premature birth and patient was <2 y of age; diabetes mellitus, includes both type I and type II; neurologic condition, any, includes cerebral palsy, chronic cognitive deficits, epilepsy/seizure/seizure disorders, multiple sclerosis, neuropathy, and others; urinary tract problems/abnormalities, a structural or functional urinary tract abnormality leading to obstruction or retention of urine as documented in the medical record; cardiovascular disease, includes congenital heart disease, congestive heart failure, prior cerebrovascular accident/stroke, peripheral vascular disease; chronic pulmonary disease, includes cystic fibrosis and any chronic respiratory condition resulting in chronic symptomatic dyspnea in medical record; chronic renal disease, includes chronic kidney disease (all stages), end-stage renal disease with or without dialysis; gastrointestinal disease, includes inflammatory bowel disease, liver disease, peptic ulcer disease, and short gut syndrome; skin condition, includes pressure ulcers, surgical wounds, other skin conditions such as eczema, psoriasis; malignancy, includes hematologic, metastatic and nonmetastatic solid organ; transplant, includes hematopoietic stem cell and solid organ.